Skip to main content

Table 1 Baseline characteristics (safety set)

From: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

Category

N = 495

Age (years); mean ± SD [range]

67.7 ± 8.98 [43–87]

Age categories; n (%)

 ≥30 to < 65

164 (33.1)

 ≥65 to < 85

325 (65.7)

 ≥85

6 (1.2)

Sex (M/F); n (%)a

315 (63.6)/179 (36.2)

Race: n (%)

 White

495 (100.0)

Duration of Parkinson’s disease (months);

 Mean ± SD

102.1 ± 59.60

 Median [range]

89 [5–420]

Duration of motor fluctuations (months);

 Mean ± SD

30.1 ± 37.97

 Median [range]

15 [0–324]

Symptoms (WOQ-9 assessment); n (%)b

 Tremor

299 (62.7)

 Any slowness of movement

459 (96.2)

 Mood changes

248 (52.0)

 Any stiffness

393 (82.4)

 Pain/aching

286 (60.0)

 Reduced dexterity

433 (90.8)

 Cloudy mind/slowness of thinking

223 (46.8)

 Anxiety/panic attacks

119 (24.9)

 Muscle cramping

288 (60.4)

Total levodopa daily dose (mg); mean ± SD

580.1 ± 289.1

Median [range]

525.0 [100–3750]

Adjunct therapies; n (%)c

 Rasagiline

136 (27.5)

 Pramipexole

123 (24.8)

 Ropinirole

111 (22.4)

 Amantadine

105 (21.2)

 Rotigotine

68 (13.7)

 Safinamide

67 (13.5)

 Piribedil

44 (8.9)

  1. an = 1 missing, bassessed in the full analysis set, cpatients could take ≥ 1 adjunct therapy